Amsterdam Movement Sciences, Section of Endocrinology, Department of Internal Medicine, Vrije Universiteit, Amsterdam University Medical Center , Amsterdam , The Netherlands.
Amsterdam Movement Sciences, Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam University Medical Center , Amsterdam , The Netherlands.
Am J Physiol Endocrinol Metab. 2019 Jan 1;316(1):E96-E105. doi: 10.1152/ajpendo.00265.2018. Epub 2018 Nov 20.
Bone marrow adipose tissue (BMAT) increases after menopause, and increased BMAT is associated with osteoporosis and prevalent vertebral fractures. Peroxisome proliferator-activated receptor-γ (PPARγ) activation promotes adipogenesis and inhibits osteoblastogenesis; therefore, PPARγ is a potential contributor to the postmenopausal increase in BMAT and decrease in bone mass. The aim of this study is to determine if PPARγ inhibition can prevent ovariectomy-induced BMAT increase and bone loss in C3H/HeJ mice. Fourteen-week-old female C3H/HeJ mice ( n = 40) were allocated to four intervention groups: sham surgery (Sham) or ovariectomy (OVX; isoflurane anesthesia) with either vehicle (Veh) or PPARγ antagonist administration (GW9662; 1 mg·kg·day, daily intraperitoneal injections) for 3 wk. We measured BMAT volume, adipocyte size, adipocyte number. and bone structural parameters in the proximal metaphysis of the tibia using polyoxometalate-based contrast enhanced-nanocomputed topogaphy. Bone turnover was measured in the contralateral tibia using histomorphometry. The effects of surgery and treatment were analyzed by two-way ANOVA. OVX increased the BMAT volume fraction (Sham + Veh: 2.9 ± 2.7% vs. OVX + Veh: 8.1 ± 5.0%: P < 0.001), average adipocyte diameter (Sham + Veh: 19.3 ± 2.6 μm vs. OVX + Veh: 23.1 ± 3.4 μm: P = 0.001), and adipocyte number (Sham + Veh: 584 ± 337cells/μm vs. OVX + Veh: 824 ± 113cells/μm: P = 0.03), while OVX decreased bone volume fraction (Sham + Veh: 15.5 ± 2.8% vs. OVX + Veh: 7.7 ± 1.9%; P < 0.001). GW9662 had no effect on BMAT, bone structural parameters, or bone turnover. In conclusion, ovariectomy increased BMAT and decreased bone volume in C3H/HeJ mice. The PPARγ antagonist GW9662 had no effect on BMAT or bone volume in C3H/HeJ mice, suggesting that BMAT accumulation is regulated independently of PPARγ in C3H/HeJ mice.
骨髓脂肪组织(BMAT)在绝经后增加,而增加的 BMAT 与骨质疏松症和普遍存在的椎体骨折有关。过氧化物酶体增殖物激活受体-γ(PPARγ)的激活促进脂肪生成并抑制成骨细胞生成;因此,PPARγ 是绝经后 BMAT 增加和骨量减少的潜在贡献者。本研究的目的是确定 PPARγ 抑制是否可以预防 C3H/HeJ 小鼠去卵巢引起的 BMAT 增加和骨丢失。将 14 周龄的雌性 C3H/HeJ 小鼠(n = 40)分为四组干预:假手术(Sham)或卵巢切除术(OVX;异氟烷麻醉),同时给予载体(Veh)或 PPARγ 拮抗剂(GW9662;1mg·kg·天,每天腹膜内注射)治疗 3 周。我们使用多金属氧酸盐基对比增强纳米计算机断层扫描测量胫骨近端干骺端的 BMAT 体积、脂肪细胞大小、脂肪细胞数量和骨结构参数。使用组织形态计量法在对侧胫骨测量骨转换。通过双因素方差分析分析手术和治疗的影响。OVX 增加了 BMAT 体积分数(Sham + Veh:2.9±2.7% vs. OVX + Veh:8.1±5.0%:P <0.001)、平均脂肪细胞直径(Sham + Veh:19.3±2.6μm vs. OVX + Veh:23.1±3.4μm:P = 0.001)和脂肪细胞数量(Sham + Veh:584±337cells/μm vs. OVX + Veh:824±113cells/μm:P = 0.03),而 OVX 降低了骨体积分数(Sham + Veh:15.5±2.8% vs. OVX + Veh:7.7±1.9%;P <0.001)。GW9662 对 BMAT、骨结构参数或骨转换没有影响。总之,卵巢切除术增加了 C3H/HeJ 小鼠的 BMAT 并减少了骨量。PPARγ 拮抗剂 GW9662 对 C3H/HeJ 小鼠的 BMAT 或骨量没有影响,这表明 C3H/HeJ 小鼠中 BMAT 的积累独立于 PPARγ 调节。